Targeting endometriosis
This study investigated whether the tyrosine kinase inhibitor pexidartinib could be a viable non-hormonal treatment for endometriosis by examining its effects on receptor tyrosine kinases.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This paper describes the rationale for targeting receptor tyrosine kinases in endometriosis, noting that the condition affects about 10% of women worldwide and that current surgery and hormone-based treatments are often ineffective. It highlights early findings from a study by Timothy Dunn and colleagues evaluating pexidartinib, an FDA-approved tyrosine kinase inhibitor, to determine whether inhibiting RTKs could reduce inflammatory signaling and cell viability in endometriosis. The text presents the work as an early preview of a potential non-hormonal treatment rather than providing detailed methods or results in the preview itself, and it does not state additional limitations beyond the restricted access context. This paper is centrally about endometriosis — it discusses targeting RTKs with pexidartinib based on early reported effects on inflammatory signaling and cell viability in endometriosis.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Full text
1,897 characters
· extracted from
oa-doi-fallback
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
- Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis 2024
- Harnessing the inflammatory processes in endometriosis 2023
Cited by (4)
- A Noninvasive Menstrual Blood-Based Diagnostic Platform for Endometriosis Using Digital Droplet Enzyme-Linked Immunosorbent Assay and Single-Cell RNA Sequencing 2025
- Liriodendrin alleviates endometriosis via PPARγ activation and inhibition of NLRP3 inflammasome-mediated pyroptosis 2026
- Leonurine microcomposite depots alleviate endometriosis and rheumatoid arthritis via shared anti-inflammatory cascades 2026
- Circ_0008927 Promotes the Progression of Endometriosis via miR-608-/PROM2-Mediated Ferroptosis 2024
References (2)
Cited by (4)
- Liriodendrin alleviates endometriosis via PPARγ activation and inhibition of NLRP3 inflammasome-mediated pyroptosis 2026
- Leonurine microcomposite depots alleviate endometriosis and rheumatoid arthritis via shared anti-inflammatory cascades 2026
- A Noninvasive Menstrual Blood-Based Diagnostic Platform for Endometriosis Using Digital Droplet Enzyme-Linked Immunosorbent Assay and Single-Cell RNA Sequencing 2025
- Circ_0008927 Promotes the Progression of Endometriosis via miR-608-/PROM2-Mediated Ferroptosis 2024
Source provenance
- europepmc
- last seen: 2026-11-17T06:10:42.428116+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-11-17T06:09:09.175860+00:00
- unpaywall
- last seen: 2026-11-17T06:36:55.820963+00:00